Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

9 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-01-23

Study Completion Date

2022-03-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will combine cabozantinib with pemetrexed to treat patients with non-small cell lung cancer, urothelial cancer and advanced malignant mesothelioma. This study will test the safety of both drugs used together and see what effect (good or bad) it has no participants and their cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

NCT03375320

Functioning Pancreatic Neuroendocrine Tumor Intermediate Grade Lung Neuroendocrine Neoplasm Locally Advanced Digestive System Neuroendocrine Neoplasm +25 more

ACTIVE_NOT_RECRUITING PHASE3

Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma

NCT04200443

Metastatic Leiomyosarcoma Metastatic Soft Tissue Sarcoma Stage III Uterine Corpus Leiomyosarcoma AJCC v8 +8 more

ACTIVE_NOT_RECRUITING PHASE2

A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum

NCT04022213

Desmoplastic Small Round Cell Tumor Peritoneal Cancer Peritoneal Carcinoma

ACTIVE_NOT_RECRUITING PHASE2

Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer

NCT06006013

Locally Advanced Adrenal Cortex Carcinoma Adrenal Cortical Carcinoma Stage III Adrenal Cortex Carcinoma +2 more

ACTIVE_NOT_RECRUITING PHASE2

Bortezomib in Treating Patients With Malignant Pleural Mesothelioma

NCT00513877

Malignant Mesothelioma

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non Small Cell Lung Cancer Non-squamous Non-small-cell Lung Cancer Urothelial Carcinoma Malignant Mesothelioma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cabozantinib + Pemetrexed

Pemetrexed 500mg/m2 IV day 1 of each 21 day cycle + Cabozantinib 20-60mg by mouth once a day.

Group Type EXPERIMENTAL

Cabozantinib

Intervention Type DRUG

start at 20mg then increase by 20mg every cycle or until there's a dose-limiting toxicity.

Pemetrexed

Intervention Type DRUG

Start with 400mg/m2, then increase and maintain 500mg/m2 unless dose-limiting toxicity.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cabozantinib

start at 20mg then increase by 20mg every cycle or until there's a dose-limiting toxicity.

Intervention Type DRUG

Pemetrexed

Start with 400mg/m2, then increase and maintain 500mg/m2 unless dose-limiting toxicity.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Locally advanced NSCLC, urothelial cancer or malignant mesothelioma.
* 18 years or older.
* At least one prior chemotherapy before entering in this trial.
* Not pregnant or breastfeeding.

Exclusion Criteria

* Prior treatment with cabozantinib.
* Currently receiving cancer treatment (last dose 2 weeks prior to enrollment in study).
* History of bleeding disorder/bleeding history within 12 weeks before first study treatment dose.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No